Investment

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Jazz targets a first‑half 2026 sBLA after statistically significant efficacy gains in HER2‑positive GEA.